WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL

Saved in:

Bibliographic Details
Main Authors:	Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924004455
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
by: Lisa Kivman, et al.
Published: (2025-02-01)

WCN25-1084 INTERNATIONAL RISK-PREDICTION TOOL IN IgAN AND THE PROGNOSTIC IMPLICATIONS OF CRESCENTS
by: Beatriz Mendes, et al.
Published: (2025-02-01)

Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy
by: Hiroyuki Ueda, et al.
Published: (2025-07-01)

Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review
by: Sarah N. Ali, et al.
Published: (2025-05-01)

WCN25-4528 POST TRANSPLANT CRESCENTIC IgAN- FIRST CASE SERIES FROM INDIA
by: NITISH THAKUR, et al.
Published: (2025-02-01)

2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation
by: Yan-Xin Tao, et al.
Published: (2025-07-01)

Exploring Novel Adverse Events of Nefecon
by: Jingyu Wang, et al.
Published: (2024-09-01)

WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS
by: Zhaoxin Chen, et al.
Published: (2025-02-01)

WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality
by: Melanie Grandits, et al.
Published: (2025-12-01)

Evaluation the Efficacy of ELISA IgG, IgM and IgA Tests for Diagnosis of Helicobacter pylori
by: Hogir Mohammed Shukri Saadi, et al.
Published: (2018-09-01)

Clinical characteristics of patients with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG
by: Qingchen Li, et al.
Published: (2025-07-01)

Enzyme linked immunosorbent assay (ELISA) for the detection of IgG, IgM, IgE and IgA against Cysticercus cellulosae in cerebrospinal fluid of patients with neurocysticercosis
by: Odashima Newton Satoru, et al.
Published: (2002-01-01)

Relationship between renal deposition of complement C3， IgG， IgM and pathology in IgA nephropathy
by: Fang-cao Lu, et al.
Published: (2022-08-01)

Detection of IgM, IgG and IgA against pertussis in pregnant women in I - II - III trimesters
by: T. A. Skirda, et al.
Published: (2021-10-01)

Estimation of Ig/M & IgG values in the serum atfer intravenois
by: Baghdad Science Journal
Published: (2005-06-01)

Kalp, Nefs ve Ruh
by: Fatih Lengerli
Published: (2022-04-01)

IgM+IgD− B cells in human gut-associated lymphoid tissue have memory features and give rise to IgM+ and IgA+ antibody-secreting cells
by: Ameera M. Bukhari, et al.
Published: (2025-07-01)

Detection of intrathecal IgM, IgG and IgA in a Cuban West Nile virus confirmed case Detección intratecal de IgM, IgG e IgA en un caso confirmado de infección por virus del Nilo Occidental en Cuba
by: Maritza Pupo-Antúnez, et al.
Published: (2008-09-01)

Feasibility of replacing 99mTc‐DTPA GFR measurements with eGFR from cystatin C in individuals with spinal cord injuries
by: Tatiana Kristensen, et al.
Published: (2025-05-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

Serum immune indicators including IgM, IgA, and IgG levels and quality of life of patients with gastrointestinal tumours during chemotherapy
by: Wan Mengchao, et al.
Published: (2025-01-01)

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]
by: Hiddo J.L. Heerspink, et al.
Published: (2025-04-01)

Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy
by: Mototsugu Tanaka, et al.
Published: (2011-01-01)

Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
by: Qiang Sun, et al.
Published: (2016-01-01)

Carboxymethyl-lysine is a Prominent Target of Circulating IgA in IgA Nephropathy
by: Sara Alibrandi, et al.
Published: (2025-07-01)

Anti-IgD nanobodies as novel tools for studying human IgD biology
by: Susan K. Vester, et al.
Published: (2025-07-01)

Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns
by: Luisa Knecht, et al.
Published: (2024-12-01)

IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01)

Human neurocysticercosis: IgE in cerebrospinal fluid Neurocisticercose humana: IgE no líquido cefalorraquiano
by: Carmen Silvia de Melo, et al.
Published: (1997-01-01)

Differentiating Secondary Dengue Cases using Capture IgG and IgM-based Approaches
by: P.R. Asish, et al.
Published: (2025-06-01)

Определение специфических IgE и IgG антител на местноанестезирующие препараты in vitro
Published: (2020-04-01)

Characteristics of adult membranous nephropathy patients with capillary co-deposition of IgG and IgA
by: Yi Guan, et al.
Published: (2025-12-01)